ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Skyler Bloom – Senior Director, Business Development & Corporate Strategy Adam Grossman – President and Chief Executive Officer Brad Tade – Chief Financial Officer and Treasurer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Anthony Petrone – Mizuho Group Gary Nachman – Raymond James Operator Thank you for standing by. My name is Celine and I will be your conference operator ...

Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.08 per share when it actually produced earnings of $0.13, delivering a surprise of 62.50%. Over the last ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (Sta ...

Exhibit 99.1 ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update 3Q 2024 Total Revenue of $119.8 Million, a 78% Increase Y-o-Y 3Q 2024 GAAP Net Income of $35.9 Million, a 1,300% Increase Y-o-Y 3Q 2024 Adjusted EBITDA(1) of $45.4 Million, a 256% Increase Y-o-Y KPMG LLP Engaged as New Independent Registered Public Accounting Firm FY 2024 and 2025 Total Revenue Guidance Increased to More Than $415 Million and $465 Million, Respectively FY 2024 and 2025 GAAP Net Income Gui ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics's Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

ADMA Biologics (ADMA) is scheduled to report third-quarter 2024 results on Nov. 7, after market close.The Zacks Consensus Estimate for sales and earnings is pegged at $107.25 million and 13 cents per share, respectively.Image Source: Zacks Investment ResearchFind the latest EPS estimates and surprises on Zacks Earnings Calendar.ADMA’s Earnings Surprise HistoryADMA has an excellent track record. ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 105.63%. I ...

Adma Biologics (ADMA) shares rallied 18.8% in the last trading session to close at $19.37. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 16.7% loss over the past four weeks.ADMA Biologics announced that KPMG will now serve as the company’s new independent registered public accounting firm effective upon the filing of its quarterly report for the fiscal quarter ended Sep. 30, 2024. Investors cheered the news ...

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics's Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

Company Overview - ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets, and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases [1] Stock Performance - ADMA Biologics stock experienced a significant decline of more than 20% during trading on October 10, 2024, following the surprise resignation of its independent outside auditor, CohnReznick LLP, on October 9, 2024 [2] Legal Investigation - Leading securities law firm Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential violations of federal securities laws [1] - Investors in ADMA Biologics are encouraged to obtain additional information and may have legal options to submit their information to the firm [2][3] Law Firm Background - Bleichmar Fonti & Auld LLP is a leading international law firm specializing in securities class actions and shareholder litigation [3] - The firm has a notable track record, including recovering over $900 million from Tesla, Inc's Board of Directors and $420 million from Teva Pharmaceutical Ind Ltd [3]

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...